Most coverage of cannabis tax policy explains Section 280E in two sentences, both of them broadly true and neither of them sufficient to understand what the April 2026 rescheduling actually changes for operators. The two sentences are: “Section 280E prevents cannabis businesses from deducting normal operating expenses, because cannabis is a Schedule I controlled substance.” And: “Schedule III rescheduling will eliminate the 280E problem.”
The first sentence is approximately correct. The second is only partially correct, in ways that determine whether a given operator gets meaningful tax relief, modest relief, or no relief at all. The structural details have been underexplained in most cannabis coverage, and the underexplanation is producing financial expectations among investors that the actual order will not meet.
This piece walks through how 280E works in practice, what the DOJ’s April 23 order specifically changes about it, and what the cash flow effect actually looks like across the three operator categories that emerge from the new framework. The mechanics are not optional knowledge if you are reading the financial statements of any cannabis operator over the next 18 months.
The statute itself
Section 280E of the Internal Revenue Code was passed in 1982 in response to a Tax Court case in which a convicted cocaine dealer had successfully deducted ordinary business expenses, including the cost of a yacht used in trafficking. Congress, finding this politically unworkable, added a provision to the tax code disallowing deductions for businesses that traffic in controlled substances listed under Schedule I or Schedule II of the federal Controlled Substances Act.
The full text is short. No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances which are prohibited by federal law. The drafters intended this to apply to illegal drug operations. They were not contemplating, in 1982, the situation of state-licensed cannabis dispensaries.
The Internal Revenue Service has applied the statute literally. Cannabis is Schedule I. State-licensed cannabis operators are, from the federal tax code’s perspective, engaged in trafficking a controlled substance prohibited by federal law. They are therefore disallowed from deducting ordinary business expenses, with one important exception: cost of goods sold.
What “cost of goods sold” includes, and what it does not
The exception for cost of goods sold (COGS) is structural, not discretionary. The U.S. Constitution requires that federal income tax be levied on income, not gross receipts. The Sixteenth Amendment’s text refers to income, which courts have consistently interpreted to mean net of the cost of producing whatever is being sold. If 280E disallowed all expenses including the cost of the product itself, the statute would effectively be levying a tax on revenue, which would be unconstitutional. The IRS therefore permits cannabis operators to deduct COGS even under 280E.
For a cannabis cultivator, COGS includes the direct costs of producing the plants: seeds, soil, water, electricity for the grow operation, labor directly associated with cultivation. For a manufacturer of cannabis products, COGS includes the cost of the raw cannabis input, the manufacturing labor, the packaging materials. These costs are deductible.
What is not deductible, for any cannabis business subject to 280E, is the entire category of expenses that any normal business would consider routine operating costs: rent for retail space, salaries of dispensary staff, marketing, advertising, professional fees, software, insurance, the costs of compliance with state regulation, security, payment processing fees, executive compensation for non-cultivation roles. None of these are deductible.
The effective result is that a state-licensed cannabis dispensary, doing exactly the same legal business as a state-licensed liquor store next door, faces a federal effective tax rate that is routinely two to three times higher. The dispensary owes federal tax on its gross profit (revenue minus COGS), with no offset for the rent, the staff, the security, or any of the costs of actually operating a retail business. The liquor store owes federal tax on its net profit, with all those expenses deducted normally. The difference is the 280E penalty.
Industry estimates of the effective federal tax rate on cannabis operators under 280E have ranged from 60 percent to over 90 percent of net economic profit, depending on the operator’s mix of revenue sources and the granularity of their cost accounting. For pure-play retail dispensaries with no cultivation, the rate is at the higher end of this range. For vertically integrated operators who can allocate more costs to deductible cultivation activities, the rate is lower but still punitive.
This is why most large multi-state operators (MSOs) report substantial GAAP net income but minimal or negative free cash flow. The income is taxed at rates that would put most non-cannabis businesses out of operation. The MSOs survive because they can absorb the tax through scale and through the limited number of competitors in licensed markets.
What the April 2026 order specifically changes
The Department of Justice issued a final order on April 23, 2026, immediately rescheduling two specific categories of cannabis from Schedule I to Schedule III. The first category: FDA-approved drug products containing marijuana. The second category: marijuana subject to a qualifying state medical marijuana license.
This is the specific scope, and the specifics matter enormously for 280E.
For the first category, FDA-approved cannabis drug products, 280E was never the binding constraint anyway. Epidiolex, Marinol, and similar products are sold through pharmacy distribution channels by pharmaceutical companies, not through state cannabis programs. Their tax treatment is unremarkable. The rescheduling formalizes this, but it does not change much in practice for operators.
For the second category, marijuana subject to a state medical marijuana license, the change is real and substantial. Operators with state medical licenses, for the activities conducted under those licenses, are no longer trafficking in a Schedule I substance for purposes of 280E. The disallowance does not apply. The operator can deduct rent, salaries, marketing, and other normal operating expenses, just like any other business. The effective federal tax rate falls from the punitive 60-to-90-percent range toward the standard corporate rate.
For all other cannabis activity, including recreational cannabis under state adult-use licenses, 280E continues to apply unchanged. The recreational side of the business is still federally Schedule I. The disallowance is still in effect.
Treasury announced on April 23 that the effective date of the rescheduling for tax purposes is January 1, 2026, with a transition rule expected. This is meaningful: it potentially makes the entire 2026 tax year eligible for 280E relief for the qualifying medical activities, even though the regulatory order itself took effect April 28.
The Cannabis Regulators Association estimates the effective tax rate for qualifying medical marijuana businesses could fall to approximately 20 to 30 percent under the new framework, measured from the order’s effective date.
The three operator categories
What this produces, in practice, is three distinct tax positions for operators across the cannabis industry.
The first category: pure-play medical operators. Businesses that hold only state medical marijuana licenses and conduct only medical-side activities. For these operators, the 280E disallowance lifts entirely on the medical activities, retroactive (subject to Treasury’s transition rule) to January 1, 2026. Free cash flow improves substantially. The largest pure-medical operators are concentrated in states that have legalized medical cannabis but not recreational, including Florida, Pennsylvania, Ohio (recently), and several smaller markets.
The second category: dual-license operators. Most large MSOs (Trulieve, Curaleaf, Green Thumb Industries, Cresco Labs, and several others) operate in multiple states under various combinations of medical and recreational licenses. For these operators, the situation is more complex. The medical-side activities qualify for relief; the recreational-side activities do not. The Treasury Department is expected to issue guidance on how to allocate expenses across the two sides of the business, but until that guidance lands, operators are working with substantial uncertainty about their effective 2026 tax position. The financial statements of dual-license MSOs for the next several quarters will need to be read carefully, with attention to how each operator is provisioning for the unresolved allocation question.
The third category: pure-recreational operators. Businesses operating only in states that have legalized recreational cannabis without a separate medical license framework, or operators who have abandoned medical licenses to focus on the larger recreational markets. For these operators, the April 2026 order changes essentially nothing on the 280E question. The disallowance continues to apply in full. Relief, if it comes, will come only if the broader administrative hearing scheduled for June 29-July 15 results in rescheduling all cannabis to Schedule III. That outcome is possible but not certain, and even if it happens the timeline for a final rule extends potentially into 2027.
What this means for reading the next round of MSO earnings
Cannabis operator earnings releases over the next two to four quarters will reflect this new framework in ways that require attention.
Expect pure-medical operators to report meaningful improvements in net income and free cash flow, beginning with the first full quarter post-effective-date (which is Q3 2026 for most operators on a calendar fiscal year). Look for explicit disclosure of the 280E relief impact, separate from organic operating performance. Operators who do not break this out are obscuring information that is material to understanding the underlying business.
Expect dual-license MSOs to report messy results. The expense allocation question between medical and recreational activities is genuinely difficult, and operators will be making provisional choices that the Treasury guidance may subsequently override. Earnings calls in Q2 and Q3 2026 will likely include extensive discussion of allocation methodology. Read these with patience and skepticism. The same business can look meaningfully different under different allocation assumptions, and operators have incentives to present whichever methodology produces the cleaner story.
Expect pure-recreational operators to report unchanged 280E positions. Any analyst commentary suggesting these operators benefit from the April order is either confused about the order’s scope or speaking aspirationally about the broader rescheduling hearing.
What this does not change
The April 2026 order does not solve the cannabis industry’s full federal-state conflict. It does not establish federal banking access. It does not address SAFE Banking, the legislation that has been stuck in Congress for years. It does not create interstate commerce in cannabis products. It does not eliminate the federal-state mismatch under which an operator can be fully licensed in one state and fully illegal in another.
It does not make cannabis investments uniformly easier. It produces a structural advantage for certain operator types over others. Investors should expect the relative competitive position of pure-medical operators to improve relative to pure-recreational operators, until and unless the broader rescheduling proceeds. The market may not yet have priced this differential fully.
It does not, finally, resolve the underlying policy question of whether the federal government is moving toward broader cannabis normalization or holding the line at medical use. The June 29 hearing will provide a signal. The years of legal challenges that will follow whatever the hearing produces will provide the actual answer.
For now, the practical effect of the April order is that 280E is bifurcated. Some cannabis businesses are now subject to it; some are not. The reading of every quarterly earnings release from now on requires knowing which is which.